Results of Phase 3 Trial Suggest The Drug Cosentyx Could be Effective for Axial Spondyloarthritis
source: pixabay.com

Results of Phase 3 Trial Suggest The Drug Cosentyx Could be Effective for Axial Spondyloarthritis

According to a story from Ankylosing Spondylitis News, findings from a phase 3 clinical trial suggest that the drug secukinumab (marketed as Cosentyx) could be an effective treatment for non-radiographic…

Continue Reading Results of Phase 3 Trial Suggest The Drug Cosentyx Could be Effective for Axial Spondyloarthritis
This Company Just Provided a Grant for a Niemann-Pick Disease Type C Screening Program
Pexels / Pixabay

This Company Just Provided a Grant for a Niemann-Pick Disease Type C Screening Program

According to a story from ir.stockpr.com, the biotechnology company Cyclo Therapeutics, Inc. (previously known as CTD Holdings) has recently thrown its support behind a Niemann-Pick Disease Type C newborn screening…

Continue Reading This Company Just Provided a Grant for a Niemann-Pick Disease Type C Screening Program

A Teenager was Killed by a Disease so Rare it Didn’t Have a Name, But His Story Could Change the Lives of Others Like Him

According to a story from NBC News, Mitchell Herndon, a 19 year old from Missouri, recently passed away due to the progression of a rare genetic disease that is so…

Continue Reading A Teenager was Killed by a Disease so Rare it Didn’t Have a Name, But His Story Could Change the Lives of Others Like Him
“It Took 23 Years to Find out I Have Fabry Disease:” A Rare Patient Story From The Czech Republic
klausdie / Pixabay

“It Took 23 Years to Find out I Have Fabry Disease:” A Rare Patient Story From The Czech Republic

Bohuslav Skoupý had trouble with his kidneys. He even had a transplant. He also had heart problems. In the end, it turned out actually by chance that Fabry disease was…

Continue Reading “It Took 23 Years to Find out I Have Fabry Disease:” A Rare Patient Story From The Czech Republic
Enrollment Begins for Amyotrophic Lateral Sclerosis Clinical Trial
DarkoStojanovic / Pixabay

Enrollment Begins for Amyotrophic Lateral Sclerosis Clinical Trial

According to a story from BioPortfolio, the biopharmaceutical company Collaborative Medicinal Development, LLC has recently announced that the first patient has been enrolled in a clinical trial that will test…

Continue Reading Enrollment Begins for Amyotrophic Lateral Sclerosis Clinical Trial

Study Reveals a More Efficient Approach for Diagnosing Certain Cases of Hereditary Angioedema

According to a story from Angioedema News, a recent study discusses a genetic procedure called allelic discrimination as a method for diagnosing hereditary angioedema. The study concluded that this method…

Continue Reading Study Reveals a More Efficient Approach for Diagnosing Certain Cases of Hereditary Angioedema
A Man with CIDP Slid 400 Feet Down the New River Gorge’s High-Line in a Wheelchair.
Free-Photos / Pixabay

A Man with CIDP Slid 400 Feet Down the New River Gorge’s High-Line in a Wheelchair.

As originally reported in WWVA, West Virginian Sib Weatherford spent one afternoon this fall doing what nobody though possible: he slid 400 feet down the New River Gorge's high-line in…

Continue Reading A Man with CIDP Slid 400 Feet Down the New River Gorge’s High-Line in a Wheelchair.

The Open Targets Initiative Brings Scientists Closer to Identifying the Cause of Autoimmune Diseases

  Scientists believe that “it is in our DNA.” According to a recent article in EurekAlert, a five-year study formulated through Open Targets together with the Sanger Institute and their…

Continue Reading The Open Targets Initiative Brings Scientists Closer to Identifying the Cause of Autoimmune Diseases

Patients Recruited for Phase 2 Study of Experimental Friedreich’s Ataxia Treatment

According to a press release from Barcelona-based biotechnology company Minoryx Therapeutics, the Company has completed enrollment for a phase 2 clinical study of its experimental Friedreich's ataxia treatment, MIN-102 (generic…

Continue Reading Patients Recruited for Phase 2 Study of Experimental Friedreich’s Ataxia Treatment